The morbidity and mortality of disease vary according to the region and may also change over time. The morbidity and mortality of malignant lymphoma are also affected by differences in ethnicity, lifestyle habits, geographical area, and time period. Increasing research on malignant lymphoma has focused on its pathophysiology, diagnosis, and therapeutic treatment. Recent improvements in the accuracy of clinical study, technologies such as next-generation sequencing, and the development of targeted molecular agents have also resulted in a number of excellent studies. This review summarizes the epidemiology of malignant lymphoma and highlights novel studies on adult T-cell leukemia/lymphoma recently published in Japan.
Frequency of subtypes of lymphoid neoplasms stratified by six areas in Japan [4, 5] , the proportions of the other subtypes did not differ significantly between regions.
Comparison to previous reports in Japan Additional studies with larger populations are necessary to investigate this trend because there were also differences in study design among these studies. Comparison of the proportions of subtypes among China, Korea, and Japan
Comparison of the proportion of subtypes in East Asia, including China [7] , Korea [8] , and Japan revealed a higher proportion of FL and ATLL cases in Japan and a higher proportion of extranodal NK/T-cell lymphoma, nasal type cases in China (Table 3) . Although the results of ATLL and extranodal NK/T-cell lymphoma are compatible to those with previous studies, to our knowledge, the difference in the proportion of FL cases has not been previously reported.
The westernization of eating habits may be one of the reasons for this observation.
Recent research on adult T-cell leukemia/ lymphoma in Japan
Large retrospective studies of ATLL Katsuya et 
Prognostic significance of soluble interleukin-2R in indolent ATLL
Katsuya et al. also investigated the prognostic factors of indolent ATLL in a retrospective study including 149 cases of chronic type and 118 cases of smoldering type ATLL [11] . Soluble interleukin-2 receptor (sIL-2R) was shown to be an independent prognostic factor among clinical features, including Shimoyama's classification [12] . Based on the sIL-2R values, cases of indolent ATLL could be classified in low (sIL-2R < 1000 U/mL), intermediate (1000-< sIL-2R < 6000 U/mL), and high risk (sIL-2R-> 6000 U/mL). The MSTs and 4-year OS were not reached (95% CI 4.6-) and were 77.6% and 5.5 years (95% CI 3.1-), 54.1%, and 1.4 years (95% CI, 0.7-2.6) and 22.1% for low, intermediate, and high-risk, respectively (P < 0.0001).
This prognostic classification by sIL-2R can be also adapted as a prediction model for disease progression because the median times to systemic chemotherapy were 8.4, 2.7, and 0.1 years, respectively (P < 0.0001). Moreover, this model can statistically stratify cases of indolent ATLL for OS and median times to systemic chemotherapy more appropriately than Shimoyama's classification based on favorable chronic, unfavorable chronic, and smoldering types. Thus, SIL-2R is expected to be used as a prognostic factor of indolent ATLL.
Genomic alterations associated with prognosis in aggressive and indolent ATLL
Based on the research from Katsuya et al. assessing clinical feature as a prognostic factor, Kataoka et al. evaluated 463 cases of ATLL to investigate the associations between genomic alterations and ATLL prognosis [13] . In 97% of cases, one or more somatic alterations, including those on phospholipase C, gamma 1 (PLCG1); protein kinase C beta (PRKCB); C-C chemokine receptor type 4 (CCR4); caspase recruitment domain-containing protein 11 (CARD11); signal transducer and activator of transcription 3 (STAT3), VAV1; tumor protein P53 (TP53); and transducin beta like 1 X-linked receptor 1 (TBL1XR1), were identified. The genetic profiles differed between aggressive type and indolent type. In comparison to the indolent type, the aggressive type showed an increased association with higher numbers of mutations, focal amplifications and deletions, hyperploid status, and cytosine-guanine dinucleotide island hypermethylation. Mutations in seven genes including PRKCB, TP53, interferon regulatory factor 4 (IRF4), interferon regulatory factor 2 binding protein 2 (IRF2BP2), tet methylcytosine dioxygenase 2 (TET2), CD58, and beta-2-microglobulin (B2M) and focal copy number alterations (CNAs) were more commonly detected in aggressive type than in indolent type. Among the genomic alterations, IRF4 and STAT3 mutations were the most significant in aggressive and indolent types, respectively.
Kataoka et al. then proposed a prognostic model that included both genetic abnormality and clinical features. In aggressive type ATLL, PRKCB mutations and PD-L1 amplifications were independent prognostic factors for poor OS as well as Japan Clinical Oncology Group Prognostic Index (JCOG-PI) high-risk categorization and older age (70 years or more). Cases of aggressive type were categorized into three groups according to the number of factors comprising age (70 years or more), PRKCB mutations, and PD-L1 amplifications. There was a significant difference in one-year OS rates among the three groups, with rates of 58% for cases with no risk factors, 45% for those with one risk factor, and 16% for those with two or more risk factors (P < 0.001). In indolent type ATLL, IRF4 mutations, PD-L1 amplifications, and CDKN2A deletions were independent prognostic factors for poor OS and the unfavorable chronic subtype in Shimoyama's classification was not significant. Cases of indolent type were categorized into two groups depending on the presence or absence of at least one factor among IRF4 mutations, PD-L1 amplifications, and CDKN2A deletions. There was a significant difference in three-year OS rates between the group including cases with no risk factors (82%) and those with at least one risk factor (30%) (P < 0.001).
This prognostic model is outstanding because it considers both clinical features and genetic abnormalities of the aggressive and indolent types. This model might be adopted in clinical practice for ATLL.
Biological significance of RHOA mutations in ATLL
RHOA mutations are commonly observed in angioimmunoblastic T-cell lymphoma (AITL) [14] . Nagata et al. investigated RHOA mutations in 203 cases of ATLL [15] . Although AITL cases with RHOA mutations always have TET2 mutations [14] , TET2 mutations were less often detected (17%) in RHOA-mutated cases of ATLL. The RHOA mutations in ATLL showed various patterns of distribution in the GTPbinding pocket. Although the primary mutation in AITL is Gly17Val [14] , the mutation hotspots in ATLL include those at the Cys16, Gly17, and Ala161 residues, among which Cys16Arg mutations were most frequent. Although the Gly17Val mutant in AITL showed little binding to GTP [14] , mutants in ATLL bound to GTP more immediately than did wild-type (WT) RHOA. The disconnection of GTP and GDP was highly promoted in the ATLL mutants. These results suggest that RHOA mutations in ATLL could increase the GDP/GTP exchange rate.
Flow cytometric analyses of ATLL cells with various RHOA mutations were performed to investigate whether differences in RHOA mutations affected the cell of origin of neoplastic cells. ATLL cells with WT RHOA, Cys16Arg, Cys16Gly, and Ala161Pro mutations were likely to be regulatory T-cells or effector T-cells due to their CD4(+), CD25(+), FoxP3(+), PD-1(−) or CD4(+), CD25(+), FOXP3(−), PD-1(−) phenotypes. On the other hand, ATLL cells with Gly17Val were considered to be memory T-cells because of their CD4(+) CD25(-) phenotypes.
Therapeutic effects of lenalidomide in ATLL
Although systemic intensive chemotherapy has been administered for the treatment of ATLL [16] , satisfactory effects have not been achieved, especially in aggressive ATLL. Ishida et al. performed a multicenter Phase II study in which lenalidomide was administered for relapsed or recurrent cases of ATLL [17] . An overall response rate of 42% was achieved, including 15% of cases with complete remission (CR), 4% unconfirmed complete remission (CRu), and 23% partial remission (PR). The ORRs were 33% cases of acute type, 57% in lymphoma type, and 50% in unfavorable chronic type. The median time to response, median time to progression, mean duration of response, median progression-free survival, and median OS were 1.9, 3.8, 5.2, 3.8, and 20.3 months, respectively. As described above, the administration of lenalidomide showed a favorable therapeutic effect for relapsed or recurrent cases of ATLL. Lenalidomide might be a possible future option for the treatment of ATLL.
Novel molecular agents in ATLL
Although various therapeutic approaches, including conventional chemotherapy, molecular-targeted agents, anti-viral drugs, and allo-HSCT have gradually improved the prognosis of ATLL, new developments are also underway. Narita et al. reported that BAY1143572, a selective inhibitor of cyclin-dependent kinase 9 (CDK9), could be an effective drug for ATLL following examination of cell lines, ATLL cells from patients, and a mouse model [18] . BAY1143572 suppressed the proliferation in a concentration-dependent manner and induced apoptosis of ATLL-derived or human T-lymphotropic virus type 1 (HTLV-1)-transformed cell lines and ATLL cells from patients by inhibiting the phosphorylation of the Ser2 site in RNAPII. The expressions of the c-Myc and Mcl-1 proteins were also down-regulated. BAY1143572 did not affect the protein expression of HTLV-1 tax and induced various changes in protein expression of HTLV-1 basic leucine zipper (HBZ). The administration of BAY1143572 after injection of ATLL cells in mice caused the suppression of tumor development, decreased liver and bone marrow tumors, reduced sIL-2R levels, and significantly prolonged OS.
Immune checkpoints in ATLL
The biological and clinical significance of tumor immunity has recently been confirmed in hematological malignancy [19] as well as in solid tumor [20, 21] . The importance of programmed cell death ligand 1 (PD-L1) has been reported in ATLL [22] . The reported cases of ATLL included those with PD-L1 expression in neoplastic cells (nPD-L1 + ATLL), those with PD-L1 expression in stromal cells (miPD-L1 + ATLL), and those without PD-L1 expression (PD-L1 − ATLL) (Fig. 1) . nPD-L1 + ATLL (MST = 7.5 months) had inferior OS compared to that of nPD-L1 − ATLL (MST = 14.5 months) (P = 0.0085). Among nPD-L1 − ATLL, miPD-L1 + ATLL (MST = 18.6 months) showed superior OS compared with that of PD-L1 − ATLL (MST = 10.2 months) (P = 0.0029). The expression of nPD-L1 and miPD-L1 maintained its prognostic value for OS Fig. 1 Criteria according to PD-L1 expression in ATLL. If PD-L1 was expressed on neoplastic cells, the case was categorized as nPD-L1-positive ATLL. If PD-L1 was not expressed on neoplastic cells, the case was considered nPD-L1-negative ATLL. Among nPD-L1-negative ATLL, if stromal cells showed PD-L1 expression, the case was considered miPD-L1-positive ATLL. If the stromal cells did not express PD-L1, the case was considered PD-L1-negative ATLL in multivariate analysis (P = 0.0322 and P = 0.0014, respectively). In nPD-L1 + ATLL, the PD-1/PD-L1 pathway may contribute to a worse prognosis as well as other malignancies. Blockade therapy of the PD-1/PD-L1 pathway might improve the prognosis of nPD-L1 + ATLL. However, in miPD-L1 + ATLL, viral infection including HTLV-1 can induce PD-L1 expression in stromal cells. The reason why miPD-L1 + ATLL shows a better prognosis is unknown; however, the PD-1/PD-L1 pathway might also function in miPD-L1 + ATLL. If the effector function works more in miPD-L1 + ATLL, blockade therapy may result in much better prognosis. The membranous expression of HLA and β2M in ATLL is also associated with better prognosis and might reflect the immune response [23] . The immune checkpoints could be closely associated with ATLL pathogenesis and progression.
